An observational study in Cerebral Infarction, Infarction, Brain and Dipeptidyl-Peptidase IV Inhibitors, sponsored by Ajou University School of Medicine. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by Ajou University School of Medicine · Observational
The goal of this observational study is to compare severity and mortality rates of acute cerebral infarction(requiring thrombolysis or endovascular recanalization) depending on the type of oral antidiabetic drug taken before the onset of cerebral infarction.
Researchers will compare the group that used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction and the group that did not use them to see the effect of DPP-4 inhibitors in reducing severity of cerebral infarction.
This is a retrospective study to see the effects of reducing the severity of cerebral infarction(requiring thrombolysis or endovascular recanalization) of DPP-4 inhibitors by comparing the survival rate after acute cerebral infarction hospitalization, discharge rate to home, and medical cost.
A. Severity of cerebral infarction and poor prognosis is mainly associated with hyperglycemia caused by diabetes, which increases the Infarction volume and hemorrhagic trasformation.
B. However, the effect of loergin blood glucose on reducing the Infarction volume and improving prognosis of cerebral infarction has not been proven.
C. Preclinical studies have demonstrated a anti-stroke effect that reduces the Infarction volume using certain anti-diabetic drugs.
D. Therefore, there is a possibility that certain anti-diabetic drugs may reduce the severity of cerebral infarction as a class effect in addition to the effect of blood sugar control.
E. This is particularly likely to exist in the DPP-4 inhibitor family identified through preclinical studies.
219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.
This study's planned enrollment of 22,119 is above the median of 335 across 72 observational studies indexed under Cerebral Infarction.
Browse Cerebral Infarction studies →Ajou University School of Medicine is the lead sponsor of 173 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This is a retrospective study using the Health Insurance Review and Assessment Service (HIRA) database in Korea.
In this database, patients with acute cerebral infarction who underwent thrombolysis(intravenous thrombolysis) or endovascular recanalization (intraarterial thrombectomy) between 2014 and 2021 is included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult (over 19 years of age)
Exclusion Criteria:
used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization) Combination therpay is acceptable.
Drug: Dipeptidyl peptidase-4 inhibitor
patients that did not use DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization)
The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
Also known as: A10BH07, EVOGLIPTIN, Suganon Tab
1-year survival rate
The survival rates of the DPP-4 inhibitor group and the non-use group are compared 1 year after the onset of severe stroke.
Time frame: Check the data one year after the onset of stroke.
90-day survival rate
The survival rates of the DPP-4 inhibitor group and the non-use group are compared 90-day after the onset of severe stroke.
Time frame: Check the data 90-day after the onset of stroke.
re-hospitalization
The re-hospitalization rates of the DPP-4 inhibitor group and the non-use group are compared after the onset of severe stroke.
Time frame: 1 year after discharge the stroke treatment.
frequency of cerebral hemorrhage
The frequency of cerebral hemorrhage rates of the DPP-4 inhibitor group and the non-use group are compared after the onset of severe stroke.
Time frame: Hospitalization period and 1 year after discharge the stroke treatment.
Rate of Intensive care unit treatment
The Intensive care unit treatment rate of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Duration of Intensive care unit
The duration of Intensive care unit of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Rate of Stroke care unit treatment
The Stroke care unit treatment rate of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Duration of Stroke care unit
The duration of Stroke care unit of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
tracheal intubation period
The tracheal intubation period of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
total hospitalization days
The total hospitalization days of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
medical expenses incurred at the time of hospitalization
The medical expenses incurred at the time of hospitalization of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Home discharge rate
The Home discharge rate of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: At the end of discharge from stroke treatment.
medical expenses after discharge from hospital
The medical expenses after discharge from hospital of the DPP-4 inhibitor group and the non-use group are compared.
Time frame: 1 year after discharge the stroke treatment.
No study locations are listed for this record.
Plan to share: No — Ajou University Hospital's IRB(Institutional Review Board) sends IRB approval documents to HIRA and conducts research with anonymized data after request. Data collected during the research process will be stored for 3 years and then properly disposed of in accordance with relevant laws.
This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ajou University School of Medicine →